Small-molecule MDM2-p53 inhibitors: recent advances

Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy

(2014) Zhuming Zhang et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Tetra-substituted imidazoles as a new class of inhibitors of the p53–MDM2 interaction

(2014) Andrea Vaupel et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Substituted piperidines as HDM2 inhibitors

(2014) Yao Ma et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development

(2014) Daqing Sun et al.   JOURNAL OF MEDICINAL CHEMISTRY

Selective and Potent Morpholinone Inhibitors of the MDM2–p53 Protein–Protein Interaction

(2014) Ana Z. Gonzalez et al.   JOURNAL OF MEDICINAL CHEMISTRY

Novel Inhibitors of the MDM2-p53 Interaction Featuring Hydrogen Bond Acceptors as Carboxylic Acid Isosteres

(2014) Ana Z. Gonzalez et al.   JOURNAL OF MEDICINAL CHEMISTRY

Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor

(2014) Yao Ma et al.   ACS Medicinal Chemistry Letters

Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011 – present)

(2013) Krzysztof Zak et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Rational Design and Binding Mode Duality of MDM2–p53 Inhibitors

(2013) Felix Gonzalez-Lopez de Turiso et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

(2013) Qingjie Ding et al.   JOURNAL OF MEDICINAL CHEMISTRY

A Potent Small-Molecule Inhibitor of the MDM2–p53 Interaction (MI-888) Achieved Complete and Durable Tumor Regression in Mice

(2013) Yujun Zhao et al.   JOURNAL OF MEDICINAL CHEMISTRY

Diastereomeric Spirooxindoles as Highly Potent and Efficacious MDM2 Inhibitors

(2013) Yujun Zhao et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development

(2013) Binh Vu et al.   ACS Medicinal Chemistry Letters

Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development

(2013) Zhuming Zhang et al.   ACS Medicinal Chemistry Letters

Discovery of novel dihydroimidazothiazole derivatives as p53–MDM2 protein–protein interaction inhibitors: Synthesis, biological evaluation and structure–activity relationships

(2012) Masaki Miyazaki et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

The central valine concept provides an entry in a new class of non peptide inhibitors of the p53–MDM2 interaction

(2012) Pascal Furet et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Lead optimization of novel p53-MDM2 interaction inhibitors possessing dihydroimidazothiazole scaffold

(2012) Masaki Miyazaki et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Structure-Based Design of Novel Inhibitors of the MDM2–p53 Interaction

(2012) Yosup Rew et al.   JOURNAL OF MEDICINAL CHEMISTRY

Ordering of the N-Terminus of Human MDM2 by Small Molecule Inhibitors

(2012) Klaus Michelsen et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

(2012) Isabelle Ray-Coquard et al.   LANCET ONCOLOGY

The p53-MDM2/MDMX axis – A chemotype perspective

(2011) Kareem Khoury et al.   MedChemComm

Patented inhibitors of p53–Mdm2 interaction (2006 – 2008)

(2010) Lutz Weber   EXPERT OPINION ON THERAPEUTIC PATENTS

Potent and Orally Active Small-Molecule Inhibitors of the MDM2−p53 Interaction

(2009) Shanghai Yu et al.   JOURNAL OF MEDICINAL CHEMISTRY